Cancer cells are masters of adaptation. While most healthy cells can shift their fuel sources to survive periods of nutrient scarcity, many tumors develop a specialized dependency on certain nutrients to fuel their rapid division. One such nutrient is glutamine, an amino acid essential for building the proteins and DNA that drive tumor growth.
This phenomenon, often called “glutamine addiction,” has long been a target for researchers. However, a major hurdle in treating cancer has been the ability of tumor cells to “pivot”—finding alternative metabolic pathways to survive even when glutamine is blocked.
New research published in Molecular Cell has identified a specific mechanism that allows this survival, and more importantly, a potential way to shut it down.
The Role of Pyruvate and the “Metabolic License”
A study led by Dr. Alexis Jourdain and Dr. Miriam Lisci at the University of Lausanne (Unil) has explored how cells bypass their need for glutamine by using carbon-rich molecules, specifically pyruvate.
The researchers discovered that for a cell to use pyruvate as an alternative fuel source, it relies on a critical mitochondrial enzyme called pyruvate carboxylase. This enzyme cannot function alone; it requires Vitamin B7 (biotin) to operate.
The study suggests that Vitamin B7 acts as a sort of “metabolic license.” When biotin is present, the enzyme is activated, allowing pyruvate to enter the cell’s energy system and compensate for a lack of glutamine. If this vitamin is removed or unavailable, the enzyme fails, the “license” is revoked, and the cell’s ability to grow and divide is severely compromised.
The FBXW7 Connection: Why Some Cancers are More Vulnerable
The research also provides a crucial link between genetic mutations and metabolic dependency. The team focused on FBXW7, a gene that is frequently mutated in various types of cancer.
The findings reveal a direct chain of causality:
1. Mutation occurs: The FBXW7 gene undergoes a mutation.
2. Enzyme depletion: This mutation causes the pyruvate carboxylase enzyme to partially disappear.
3. Metabolic trap: Without this enzyme, the cell can no longer use pyruvate efficiently.
4. Dependency: The cancer cell becomes trapped in a state of absolute dependence on glutamine.
This is a significant finding because it identifies a specific subset of patients—those with FBXW7 mutations—who may be much more susceptible to treatments that target glutamine metabolism.
Implications for Future Cancer Therapy
For years, clinical trials attempting to block glutamine have seen mixed results. This study helps explain why: cancer cells are not static; they are metabolically flexible. If one pathway is blocked, they simply switch to another, such as the pyruvate pathway.
By understanding this “backup plan,” scientists can move toward more sophisticated treatment models. Instead of targeting a single nutrient, future therapies may focus on simultaneous metabolic disruption —blocking both the primary fuel (glutamine) and the backup mechanism (the biotin-dependent pyruvate pathway).
“This research opens up new avenues for designing innovative therapeutic strategies that take into account the great metabolic flexibility of tumor cells,” concludes Alexis Jourdain.
Conclusion
By identifying how Vitamin B7 and the enzyme pyruvate carboxylase allow cancer cells to bypass nutrient shortages, researchers have uncovered a new vulnerability that could lead to more effective, multi-targeted cancer treatments.
